Two Newly Funded Treatments For Prostate Diseases

1 October 2008 - PHARMAC is to begin funding treatments for two types of prostate disease in men - prostate cancer and benign prostatic hyperplasia (BPH).

Pharmac, GE Free, Ownership At Risk In US Trade Deal

The Green Party is calling on the Government to make a public commitment not to weaken Pharmac and not to weaken laws on genetic engineering or foreign ownership in any trade deal with the United States.

Blue: Action On Eltroxin Now Urgent

8 September 2008 - Immediate action is needed to resolve an unfolding crisis of ill health from a new formulation of Eltroxin, a medicine used to treat an underactive thyroid, says National Party Associate Health spokeswoman Jackie Blue.

Ground-Breaking Report Into Drug Accessibility

Calls for urgent action to raise NZ from bottom of OECD

The Collaborative Forum into High Cost, Highly Specialised medicines released its report today after a three-month examination of accessibility to medicines in New Zealand.

Blue: Thyroxine Concern Needs Sorting Out

National Party Associate Health spokeswoman Jackie Blue is calling on Health Minister David Cunliffe to sort out the confusion and concern around the drug Eltroxin.

Increased Condoms Range A Win-Win - Pharmac

Funding a wider range of condoms saves taxpayers money, increases choice and promotes better sexual health practices, PHARMAC says.

Study To Explore Modern Meanings Of Medication

20 August 2008 - A psychology study on medication use will explore the symbolic significance, rather than the pharmacological function, of drugs and health remedies in the daily lives of New Zealanders.

Once-a-Day Treatment For ADHD Funded

19 August 2008 - A once-a-day treatment for people with ADHD, (Attention Deficit Hyperactivity Disorder) is being funded from 1 September.

Pharmac Funds New Treatment For Skin Cancers

13 August 2008 - A new treatment is being funded for people with a generally non-malignant form of skin cancer.

Herceptin: Keeping Faith With Clinical Trial Participants

The recent decision of PHARMAC not to fund 12 months of adjuvant Herceptin for women with Her 2 positive breast cancer calls into question our carefully crafted approach to ethical clinical trials research in cancer.